secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001650664-25-000086
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine stockholders approve increase in authorized shares and amend 2015 Stock Incentive Plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to increase authorized common stock from 195M to 390M shares; total capital stock from 200M to 395M.
- Stockholders approved amendment and restatement of 2015 Stock Incentive Plan, extending term to 10 years and eliminating evergreen provision.
- Re-elected Jessica Hopfield, Ph.D., and David Scadden, M.D. as Class III directors until the 2028 annual meeting.
- Advisory vote on executive compensation passed with ~60% for; one-year frequency for future say-on-pay votes approved.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/0001650664-25-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/edit-20250529.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer